Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Division of Urology, Department of Surgery, University of Nevada Reno School of Medicine; Department of Physiology and Cell Biology, University of Nevada Reno School of Medicine, University of Nevada Reno, Reno, NV, USA.
J Robot Surg. 2024 Jun 7;18(1):244. doi: 10.1007/s11701-024-01997-5.
Robotic partial nephrectomy (RPN) is a gold standard treatment for focal kidney tumors. Off-clamp RPN avoids prolonged ischemia times. We sought to evaluate the safety and efficacy of off-clamp RPN in patients with renal tumors > 4 centimeters (cm). From 2007 to 2021, we examined patients who underwent RPN for cT1b-T2N0M0 renal tumors. Preoperative, intraoperative, and postoperative outcomes were examined for patients who underwent on or off-clamp RPN. Patients with cT1b tumors (4-7 cm) who underwent either approach were retrospectively propensity-matched based on renal function and tumor size. Of 225 patients, on-clamp RPN was employed in 147 patients, while 78 patients underwent an off-clamp approach. Preoperative estimated glomerular filtration rate (eGFR) was significantly lower in the off-clamp group (p = 0.026). Mean nephrometry scores and mean tumor sizes were similar between cohorts. Average estimated blood loss (EBL) and operative times were similar. Major complication risk was 4.4% lower in the off-clamp group. Blood transfusion rate was 5.6% lower in the off-clamp group. Patients in the off-clamp cohort experienced a < 2% higher risk of positive margins. Postoperative eGFR was more favorable for off-clamp RPN following surgery at 1 year. The propensity-matched analysis demonstrated similar intraoperative outcomes. Blood transfusion rate was significantly lower at 1.5% for patients who underwent off-clamp RPN (p = 0.03). Risk of a major complication was 6.1% lower in the off-clamp RPN cohort, while postoperative eGFR and positive margin rates were similar between off and on-clamp groups. A non-inferior approach for patients with cT1b-T2N0M0 and moderately complex localized renal masses is off-clamp RPN.
机器人辅助部分肾切除术(RPN)是治疗局灶性肾肿瘤的金标准。无夹闭 RPN 可避免长时间缺血。我们旨在评估无夹闭 RPN 在肾肿瘤 > 4 厘米(cm)患者中的安全性和有效性。2007 年至 2021 年,我们检查了接受 RPN 治疗 cT1b-T2N0M0 肾肿瘤的患者。对接受夹闭或无夹闭 RPN 的患者进行了术前、术中、术后的结果检查。根据肾功能和肿瘤大小,回顾性地对接受两种方法治疗的 cT1b 肿瘤(4-7 cm)患者进行倾向评分匹配。在 225 例患者中,147 例患者采用夹闭 RPN,78 例患者采用无夹闭方法。无夹闭组的术前估算肾小球滤过率(eGFR)显著较低(p = 0.026)。两组的平均肾切除术评分和平均肿瘤大小相似。平均估计失血量(EBL)和手术时间相似。无夹闭组的主要并发症风险低 4.4%。无夹闭组的输血率低 5.6%。无夹闭组的阳性切缘率高 < 2%。无夹闭 RPN 术后 1 年 eGFR 更有利。倾向评分匹配分析显示术中结果相似。无夹闭 RPN 患者的输血率明显较低(1.5%,p = 0.03)。无夹闭 RPN 组的主要并发症风险低 6.1%,而术后 eGFR 和阳性切缘率在无夹闭和夹闭组之间相似。对于 cT1b-T2N0M0 和中度复杂局限性肾肿块的患者,非劣效方法是无夹闭 RPN。